Ardelyx (ARDX) has drawn investor attention after recent trading, with the stock closing at $5.20 and showing mixed returns over the past month and the past 3 months.

Over a longer window, Ardelyx’s recent share price pullback, including a 30 day share price return down 10.96% and a 90 day share price return down 19.38%, contrasts with its 1 year total shareholder return of 17.91% and 5 year total shareholder return above 200%. This suggests shorter term momentum has faded while longer term holders have still seen meaningful gains.

If you are weighing Ardelyx against other opportunities in healthcare, this is a good moment to see what else is on your radar with 39 healthcare AI stocks

After a sharp pullback yet still solid multi year returns, Ardelyx now sits at a level where opinions split. Is most of the upside already reflected in the stock, or does the current price still leave meaningful room ahead based on valuation?

Most Popular Narrative: 68.2% Undervalued

Against Ardelyx’s last close at $5.20, the most followed narrative points to a fair value of about $16.33, creating a wide valuation gap based on detailed revenue and margin assumptions.

The rising prevalence of chronic kidney disease (CKD) and gastrointestinal disorders driven by an aging population continues to expand Ardelyx's core addressable markets, supporting sustained long-term demand for IBSRELA and XPHOZAH and driving future revenue growth. Recent and ongoing improvements in market access, prescription pull-through, and expansion of the sales force are boosting prescriber breadth and depth, contributing to accelerating product adoption and positioning the company to achieve strong topline growth and improved gross margins as fixed costs are leveraged.

Want to see how this view interprets today’s losses in the context of potential future profits on paper? The narrative relies on rapid revenue expansion and sharply higher margins, leading to a valuation that also incorporates a richer earnings multiple than the wider biotech sector.

Result: Fair Value of $16.33 (UNDERVALUED)

However, Ardelyx’s reliance on just IBSRELA and XPHOZAH, along with its exposure to reimbursement decisions such as Medicare coverage for XPHOZAH, could quickly challenge this optimistic setup.

Next Steps

If this Ardelyx narrative seems finely balanced between concern and optimism, consider reviewing the data now so you can weigh both sides for yourself with 4 key rewards and 1 important warning sign

Looking for more ideas beyond Ardelyx?

Before moving on from Ardelyx, give yourself a broader view of the market by checking a few focused stock lists that highlight different ways to build a stronger portfolio.

• Target potential mispricing by scanning companies that screen well on quality and value using the 47 high quality undervalued stocks
• Prioritize stability by reviewing companies that show resilient financial profiles through the 84 resilient stocks with low risk scores
• Hunt for fresh opportunities off the beaten path with the screener containing 20 high quality undiscovered gems

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.